CD40L-Tri, a novel formulation of recombinant human CD40L that effectively activates B cells

@inproceedings{Naito2012CD40LTriAN,
  title={CD40L-Tri, a novel formulation of recombinant human CD40L that effectively activates B cells},
  author={Masayasu Naito and Ursula Hainz and Ute E. Burkhardt and Buyin Fu and Deborah Ahove and Kristen E. Stevenson and Mohini Rajasagi and Baogong Zhu and Anselmo Alonso and Elizabeth A Witten and Ken-ichi Matsuoka and Donna S Neuberg and Jonathan S Duke-Cohan and Catherine J. Wu and Gordon J Freeman},
  booktitle={Cancer Immunology, Immunotherapy},
  year={2012}
}
CD40L has a well-established role in enhancing the immunostimulatory capacity of normal and malignant B cells, but a formulation suitable for clinical use has not been widely available. Like other TNF family members, in vivo and in vitro activity of CD40L requires a homotrimeric configuration, and growing evidence suggests that bioactivity depends on higher-order clustering of CD40. We generated a novel formulation of human recombinant CD40L (CD40L-Tri) in which the CD40L extracellular domain… CONTINUE READING
Highly Cited
This paper has 17 citations. REVIEW CITATIONS

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 11 extracted citations

Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1).

Proceedings of the National Academy of Sciences of the United States of America • 2013
View 4 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 27 references

Graft-versus-leukemia antigen CML66 elicits coordinated B-cell and T-cell immunity after donor lymphocyte infusion.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2010
View 1 Excerpt